phrykt

Keros Therapeutics, Inc. (KROS): who owns it and who trades it

As of Nov 16, 2026, KROS insiders reported 12 open-market sales worth $500K and 6 purchases worth $75.8K in the last 12 months, with 15% of the sale value made under pre-set 10b5-1 plans. The largest seller was Esther Cho (Vice president), with $124K. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Keros Therapeutics

From the latest filings

Overall: about as much buying as selling. Famous investors mostly sold. Funds and insiders were close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns KROS

131 funds and institutions reported KROS shares worth $215M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Nantahala Capital Management, LLC with 14.3%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Nantahala Capital Management, LLC14.3%
BlackRock, Inc.14.2%
AQR Capital Management LLC4.9%
Vanguard Capital Management LLC4.2%
Orbimed Advisors LLC3.9%
Federated Hermes, Inc.3.6%
Vanguard Portfolio Management LLC3.3%
Mackenzie Financial Corp3.2%
Madison Avenue Partners, LP3.2%
Qube Research & Technologies Ltd3.1%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Nantahala Capital Management, LLC2.82M14.31%$30.2M+107%
BlackRock, Inc.2.79M14.17%$29.9M+16%
AQR Capital Management LLC967,8594.91%$10.4M+138%
Vanguard Capital Management LLC833,5964.23%$8.9M+0%
Orbimed Advisors LLC759,1553.85%$8.1MNo change
Federated Hermes, Inc.700,4273.55%$7.5M+2%
Vanguard Portfolio Management LLC652,6353.31%$7M-4%
Mackenzie Financial Corp628,4383.19%$6.7M+312%
Madison Avenue Partners, LP626,5833.18%$6.7MNo change
Qube Research & Technologies Ltd608,8373.09%$6.5M-16%
Jacobs Levy Equity Management, Inc605,4453.07%$6.5M-14%
State Street Corp541,1932.74%$5.8M-4%
Geode Capital Management, LLC510,8412.59%$5.5M-25%
Dimensional Fund Advisors LP460,5412.34%$4.9M+43%
Citadel Advisors LLC396,0982.01%$4.2M-3%
Renaissance Technologies LLC359,0861.82%$3.8M-21%
D. E. Shaw & Co., Inc.267,4601.36%$2.9M-48%
Bridgeway Capital Management, LLC265,0171.34%$2.8M+36%
Nuveen, LLC247,7561.26%$2.7M-5%
ADAR1 Capital Management, LLC246,8181.25%$2.6M+154%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, KROS insiders reported $75.8K of open-market purchases and $500K of sales. 15% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$75.8K
6 trades, 1 people
Sales, 12 months
$500K
12 trades, 9 people
Sales under a 10b5-1 plan
15%
Share of sale value
Latest trade
Nov 12, 2026
Filed Nov 16, 2026

Purchases and sales by month

$332K$332KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 12, 2026Anne PrenerDirectorSale plan574$9.79$5.6KForm 4
Aug 18, 2026Annita TaniniVice presidentSale1,224$10.29$12.6KForm 4
Aug 18, 2026Lorena Raquel LernerChief Scientific OfficerSale3,568$10.29$36.7KForm 4
Aug 18, 2026Esther ChoChief Legal OfficerSale4,485$10.29$46.2KForm 4
Aug 18, 2026Charles W. NewtonDirectorSale plan551$10.30$5.7KForm 4
Aug 17, 2026Jean Jacques BienaimeDirectorPurchase plan1,000$10.27$10.3KForm 4
Jul 15, 2026Jean Jacques BienaimeDirectorPurchase plan1,000$10.61$10.6KForm 4
Jun 15, 2026Jean Jacques BienaimeDirectorPurchase plan1,000$10.19$10.2KForm 4
Jun 11, 2026Charles W. NewtonDirectorSale plan550$10.04$5.5KForm 4
Jun 4, 2026Nima FarzanDirectorSale plan2,625$10.73$28.2KForm 4
Jun 4, 2026Alpna SethDirectorSale plan2,625$10.72$28.1KForm 4
May 15, 2026Jean Jacques BienaimeDirectorPurchase plan1,000$10.58$10.6KForm 4
Apr 15, 2026Jean Jacques BienaimeDirectorPurchase plan1,000$11.70$11.7KForm 4
Mar 9, 2026Jean Jacques BienaimeDirectorPurchase plan2,000$11.21$22.4KForm 4
Feb 19, 2026Jasbir SeehraCEOSale7,015$16.17$113KForm 4
Feb 18, 2026Lorena Raquel LernerChief Science OfficerSale3,873$16.35$63.3KForm 4
Feb 18, 2026Esther ChoVice presidentSale4,745$16.35$77.6KForm 4
Feb 18, 2026Keith RegnanteCFOSale4,739$16.35$77.5KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Esther ChoSVP, General Counsel–$124KAug 18, 2026
Jasbir SeehraCHIEF EXECUTIVE OFFICER, Director–$113KFeb 19, 2026
Lorena Raquel LernerChief Science Officer–$100KAug 18, 2026
Keith RegnanteCHIEF FINANCIAL OFFICER–$77.5KFeb 18, 2026
Jean Jacques BienaimeDirector$75.8K–Aug 17, 2026
Nima FarzanDirector–$28.2KJun 4, 2026
Alpna SethDirector–$28.1KJun 4, 2026
Annita TaniniCorp. Controller & VP, Finance–$12.6KAug 18, 2026
Charles W. NewtonDirector–$11.2KAug 18, 2026
Anne PrenerDirector–$5.6KNov 12, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

KROS short interest

Moderate short interest. 5.5% of KROS shares are sold short: about 1 share in 18. Over the last 12 reports the number of shares short went down 36%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 1.09M KROS shares were sold short, 5.5% of the shares outstanding, down 4.4% from the report before. At the average daily volume of 153,862 shares, buying them all back would take about 7.1 trading days (days to cover).

Shares short, % of all shares

5.54%May 15Oct 309.19%

Days to cover

7.1May 15Oct 3010.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20261.09M5.54%-4%153,8627.1
Oct 15, 20261.14M5.73%-1%174,6126.5
Sep 30, 20261.15M5.80%-14%205,0205.6
Sep 15, 20261.34M6.77%+15%147,0529.1
Aug 31, 20261.17M5.88%+1%191,3016.1
Aug 14, 20261.15M5.79%+17%242,9514.7
Jul 31, 2026985,5904.97%-7%166,3975.9
Jul 15, 20261.06M5.37%+3%259,2824.1
Jun 30, 20261.03M5.21%-27%403,7592.5
Jun 15, 20261.41M7.14%-7%213,2686.6
May 29, 20261.51M7.65%-11%332,4034.5
May 15, 20261.70M8.64%+20%366,4934.7

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Keros Therapeutics company events

Keros Therapeutics filed 19 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026AnnouncementShared information with investors. Filing
  2. Nov 5, 2026ResultsReleased financial results. Filing
  3. Sep 29, 2026AnnouncementShared information with investors. Filing
  4. Sep 28, 2026AnnouncementShared information with investors. Filing
  5. Sep 8, 2026AnnouncementKeros Therapeutics, Inc., a Delaware corporation, issued a press release announcing that the board of directors of the Company has approved a new stock repurchase program for up to $5 million of the Company’s common stock following receipt of a $20 million development milestone payment under the… Filing
  6. Aug 3, 2026AnnouncementShared information with investors. Filing
  7. Aug 3, 2026ResultsReleased financial results. Filing
  8. Jul 30, 2026AnnouncementShared information with investors. Filing
  9. Jul 22, 2026LeadershipKeith Regnante resigned from his role as Chief Financial Officer of Keros Therapeutics, Inc., effective August 3, 2026, to pursue other opportunities. Filing
  10. Jun 25, 2026LeadershipThe board of directors of Keros Therapeutics, Inc., based upon a recommendation from the Nominating and Corporate Governance Committee of the Board, voted to appoint Anne Prener, M.D., Ph.D., as a director of the Company, effective on July 1, 2026. Filing
  11. Jun 3, 2026VoteReported shareholder vote results. Filing
  12. Jun 1, 2026AnnouncementShared information with investors. Filing
  13. May 14, 2026ResultsReleased financial results. Filing
  14. Mar 9, 2026AnnouncementKeros Therapeutics, Inc. issued a press release announcing that it has entered into an agreement with the Massachusetts General Hospital for the design of a Phase 2 clinical trial evaluating rinvatercept in patients with amyotrophic lateral sclerosis within the HEALEY ALS MyMatch program, led by… Filing
  15. Mar 4, 2026AnnouncementShared information with investors. Filing
  16. Mar 4, 2026ResultsReleased financial results. Filing
  17. Feb 26, 2026LeadershipThe board of directors of Keros Therapeutics, Inc., based upon a recommendation from the Nominating and Corporate Governance Committee of the Board, voted to appoint Charles Newton as a director of the Company, effective on March 9, 2026. Filing
  18. Feb 18, 2026AnnouncementShared information with investors. Filing
  19. Jan 9, 2026AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Keros Therapeutics financials

Famous investors that hold KROS

5 of the 50 well-known investors we track reported holding KROS in their latest 13F filing. The largest position is Jim Simons's, worth $3.9M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 2026346,127$3.9M0.0%-4%
Ken Griffin · Citadel AdvisorsQ3 2026162,695$1.9M0.0%-59%
Israel Englander · Millennium ManagementQ3 202676,760$875K0.0%-58%
Steve Cohen · Point72 Asset ManagementQ3 202666,680$760K0.0%+542%
Paul Tudor Jones · Tudor Investment CorpQ3 202620,373$232K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named KROS in the last 120 days.

FiledHolderFormStake
Oct 27, 2026BlackRock Portfolio Management LLC13G/A9.1%
Oct 27, 2026BlackRock Portfolio Management LLC13G/A9.1%

Questions about Keros Therapeutics, Inc. (KROS) stock

Who owns the most KROS stock?

The largest reported owner of Keros Therapeutics, Inc. (KROS) is Nantahala Capital Management, LLC, with 14.3% of the company. In total, 131 funds and institutions reported holding KROS at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are KROS insiders buying or selling?

In the last 12 months, KROS insiders reported 6 open-market purchases worth $75.8K and 12 sales worth $500K. The latest trade was on Nov 12, 2026. See every trade.

What is the short interest in KROS?

As of Oct 30, 2026, 1.09M KROS shares were sold short, 5.5% of the shares outstanding, down 4.4% from the report before. At the average daily volume of 153,862 shares, buying them all back would take about 7.1 trading days (days to cover). See the history.

Which famous investors hold KROS?

5 of the 50 well-known investors we track reported KROS in their latest 13F filing, including Jim Simons, Ken Griffin, Israel Englander. The largest position is worth $3.9M. See all holders.

Executive pay

Keros Therapeutics's chief executive was paid a total of $2.5M for the year ended Dec 31, 2025, down 60% from $6.3M the year before. In the last 12 months, Keros Therapeutics's executives and directors bought $75.8K of stock on the open market and sold $500K.

Chief executive, total pay$2.5MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$3.7MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.2MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.